salofalk 250mg gastro-resistant tablet
dch auriga (malaysia) sdn. bhd. - 5-amino salicylic acid(5-asa),mesalazine -
salofalk 500mg gastro-resistant tablets
dch auriga (malaysia) sdn. bhd. - 5-amino salicylic acid(5-asa),mesalazine -
ntp-5-aminosalicylic acid tablet (enteric-coated)
teva canada limited - mesalazine - tablet (enteric-coated) - 400mg - mesalazine 400mg - anti-inflammatory agents
mesalazine espl 1600 milligram modified-release tablets
espl regulatory consulting limited - mesalazine - modified-release tablets - 1600 milligram - aminosalicylic acid and similar agents
mesalazine 1.2 takeda (mesalazine) 1.2 g prolonged release tablet blister pack
takeda pharmaceuticals australia pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: methacrylic acid copolymer; purified talc; silicon dioxide; sodium starch glycollate; stearic acid; iron oxide red; carmellose sodium; carnauba wax; magnesium stearate; titanium dioxide; macrogol 6000; triethyl citrate - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis.
salofalk granules mesalazine 3g modified release granules sachet
dr falk pharma australia pty ltd - mesalazine, quantity: 3000 mg - granules, modified release - excipient ingredients: aspartame; carmellose sodium; microcrystalline cellulose; citric acid; hypromellose; magnesium stearate; methylcellulose; povidone; colloidal anhydrous silica; simethicone; sorbic acid; purified talc; titanium dioxide; triethyl citrate; methacrylic acid copolymer; flavour - salofalk granules granules are indicated in the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis.
salofalk granules mesalazine 1.5g modified release granules sachet
dr falk pharma australia pty ltd - mesalazine, quantity: 1500 mg - granules, modified release - excipient ingredients: sorbic acid; magnesium stearate; triethyl citrate; hypromellose; methylcellulose; aspartame; povidone; purified talc; microcrystalline cellulose; methacrylic acid copolymer; carmellose sodium; simethicone; citric acid; colloidal anhydrous silica; titanium dioxide; flavour - salofalk granules are indicated for the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis.
salofalk mesalazine 500mg enteric coated tablet blister pack
dr falk pharma australia pty ltd - mesalazine, quantity: 500 mg - tablet, enteric coated - excipient ingredients: sodium carbonate; glycine; povidone; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; calcium stearate; hypromellose; methacrylic acid copolymer; purified talc; titanium dioxide; iron oxide yellow; macrogol 6000; basic butylated methacrylate copolymer - salofalk granules and tablets are indicated in the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis. treatment of acute episodes and maintenance of remission of crohn's ileitis and colitis.
mezavant mesalazine 1.2 g gastro-resistant, prolonged release tablet blister pack
takeda pharmaceuticals australia pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: methacrylic acid copolymer; purified talc; silicon dioxide; sodium starch glycollate; stearic acid; iron oxide red; carmellose sodium; carnauba wax; magnesium stearate; titanium dioxide; macrogol 6000; triethyl citrate - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis.
salofalk 500 suppositories
dch auriga (malaysia) sdn. bhd. - 5-amino salicylic acid(5-asa),mesalazine -